tafamidis meglumine
pfizer
['pfizer']
a post-hoc analysis of #attract and lte data examining the efficacy of continuous #ttrstabilizer in #octogenerian patients (aged 80 years) with #attrcm demonstrated better outcomes than patients who initially received placebo. learn more at #acc2023 (1065-05) 
Communicating emerging, trusted scientific information to healthcare professionals (HCPs). Pfizer sponsored, intended for U.S. HCPs. https://t.co/s5bPfuTvDc